niacin and Muscular Diseases studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Muscular Diseases: Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.

Research Excerpts

Excerpt	Relevance	Reference
" Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins."	4.81	Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001)
" Laboratory data revealed elevation of myolytic enzyme, hypokalemia and decrease of niacin level in the blood."	3.68	[A case of alcoholism presenting pellagra and hypokalemic myopathy]. ( Fukazawa, T; Hamada, T; Moriwaka, F; Shinpo, K; Tashiro, K, 1993)
"Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain."	2.78	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. ( , 2013)
" Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates."	2.71	Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. ( Rubenfire, M, 2004)
"Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events."	2.40	Combination drug therapy for combined hyperlipidemia. ( Guyton, JR, 1999)

Research

Studies (27)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Cardiovascular Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (25.93)	18.7374
1990's	3 (11.11)	18.2507
2000's	7 (25.93)	29.6817
2010's	10 (37.04)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Streja, E	1
Streja, DA	1
Soohoo, M	1
Kleine, CE	1
Hsiung, JT	1
Park, C	1
Moradi, H	1
Landmesser, U	1
Rosenson, RS	1
Gotto, AM	1
Nicholls, SJ	1
Robinson, JG	1
Lee, T	1
Arcinegas-Rodriguez, S	1
Gaspers, MG	1
Lowe, MC	1
Maningat, P	1
Breslow, JL	1
Boden, WE	1
Probstfield, JL	1
Anderson, T	1
Chaitman, BR	1
Desvignes-Nickens, P	1
Koprowicz, K	1
McBride, R	1
Teo, K	1
Weintraub, W	1
Xydakis, AM	1
Jones, PH	1
ZYLMANN, G	1
EBRAHIM, GJ	1
HADDOCK, DR	1
Rubenfire, M	1
McKenney, JM	1
Gharavi, AG	1
Diamond, JA	1
Smith, DA	1
Phillips, RA	1
Guyton, JR	1
Jacobson, TA	1
Goldstein, MR	1
Litin, SC	1
Anderson, CF	1
Shinpo, K	1
Fukazawa, T	1
Hamada, T	1
Moriwaka, F	1
Tashiro, K	1
Fransen, H	1
Endtz, LJ	1
Lambertz, J	1
Paupe, J	1
Bertaud, J	1
Vialatte, J	1
Wadia, NH	1
Swami, RK	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Relationships Between Lipoprotein(a) Levels and Aortic Valve Calcification in Patients With Heterozygous Familial Hypercholesterolemia[NCT02976818]		173 participants (Actual)	Observational	2017-04-30	Completed
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289]	Phase 3	3,414 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.)
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease[NCT02992548]	Phase 4	62 participants (Actual)	Interventional	2015-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.

Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization

Intervention	participants (Number)
ERN + Simvastatin	45
Placebo + Simvastatin	38

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.

Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	282
Placebo + Simvastatin	274

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	171
Placebo + Simvastatin	158